The macula is a small spot in the central retina that handles central vision, and pigments such as lutein and zeaxanthin concentrate there.The macula is a ~5mm yellow spot in the central retina responsible for central vision, color vision, and fine detail (reading, face recognition). Its yellow color comes mainly from lutein and zeaxanthin, plus a third pigment, meso-zeaxanthin (a different stereo-form of the zeaxanthin molecule, generally thought to be made in the retina from lutein). These pigments concentrate in the macula, reaching 1000x plasma levels.
2 · Dual function: filter + antioxidant
Lutein and zeaxanthin filter out some blue light and quench reactive oxygen species as antioxidants, shielding the retina, the most oxidation-prone site in the body.They do two things: ① absorb blue light at 400-500nm, filtering some before it reaches photoreceptors, reducing photo-oxidative damage; ② act as antioxidants quenching reactive oxygen species. The retina is one of the most metabolically active tissues, with -rich membranes under constant light — the most oxidation-prone site in the body.
3 · Age-related macular degeneration
With age the RPE clears shed photoreceptor membranes less efficiently, waste piles up as drusen and the cells slowly die, which is AMD.Retinal pigment epithelium (RPE) daily phagocytoses shed photoreceptor outer segments. With age, clearance declines, waste accumulates as drusen, and RPE/photoreceptors slowly die — that is AMD. The filter and antioxidant roles of lutein/zeaxanthin are thought to ease the light-driven oxidative pressure on this process; at most they slow progression, and they cannot reverse existing damage.
4 · The AREDS2 evidence
In people with intermediate macular degeneration, adding lutein/zeaxanthin did not significantly reduce progression, but it could replace beta-carotene, which carried a lung-cancer signal.AREDS2 (2013 JAMA): 4,203 people who already had intermediate macular degeneration, or late disease in one eye, followed for a median of 5 years; the endpoint was progression to late macular degeneration. The results have to be read in two layers.
Main comparison: adding lutein/zeaxanthin on top of the original AREDS formula gave a for progression to late disease of 0.90 (98.7% 0.76-1.07), which was not statistically significant; adding fish oil, or both, was no different.
The swap: removing beta-carotene did not make progression worse and dropped its lung-cancer signal (2.0% vs 0.9%, mostly in people who had already quit smoking), so the researchers concluded that lutein/zeaxanthin could replace it. The formula given to people with intermediate disease today is that swapped version.
In exploratory secondary analyses, people taking lutein/zeaxanthin progressed slightly less than people taking beta-carotene; analyses like this are a lead, not the main result.
Key: this is a formula for people who already have intermediate disease, not prevention, and it cannot reverse late macular degeneration. Food sources: dark leafy greens (spinach, kale), egg yolks.